Please check back often to keep up with new tests being offered, as well as other timely information regarding laboratory operations.
These updates will include changes to policies, procedures, new tests, as well as test requirements.
Please also sign up for our newsletter. This newsletter will be periodically emailed to you and will contain news and media regarding Lenco Diagnostic Laboratories, Inc., as well as information on a variety of additional health-related topics.
pdf After-hours Specimen Transport – Warm Weather.pdf
The Lenco lockbox is provided for your convenience to leave laboratory specimens for pickup after your office closes. It is important to note that the lock-box needs to be left in an area that is accessible to our couriers. If the lockbox is left inside an office building, please ensure that the courier will have entry access to the building. We recommend that the lockbox be placed in a location that is not subject or exposed to extreme temperatures.
pdf Onclarity HPV.pdf
Onclarity™ HPV allows clinicians to receive more actionable information, faster with separate on-demand reporting of high risk genotypes 16, 18 and 45 without any additional lab testing required.2 It is a multiplexed real-time PCR assay for the qualitative detection of the 14 high risk HPV genotypes.
pdf FilmArray Gastrointestinal Panel.pdf
The FilmArray GI Panel is a qualitative multiplexed diagnostic test that simultaneously detects and identifies nucleic acids from multiple bacteria, viruses, and parasites directly from stool samples obtained from individuals with signs and/or symptoms of gastrointestinal infection.
pdf Prostate Health Index (PHI) Test.pdf
The Prostate Health Index is a simple blood test that is nearly 3 times more specific in detecting prostate cancer than PSA testing alone.
pdf Thrombophilia Risk Panel.pdf
Lenco Laboratory is pleased to announce we now offer Thrombophilia Risk Panel. Utilizing innovative PCR technology for determination of genotyping, as well as providing a complete picture of inherited risk and aiding in individualized treatment decision-making.
pdf QuantiFERON – TB Gold Plus Test.pdf
Quantiferon TB Gold-Plus is an in vitro diagnostic test for detection of Mycobacterium tuberculosis infection. It is an indirect test for M.tuberculosis infection (including disease), therefore, interpretation and results should always include a risk assessment, radiography and other medical and diagnostic evaluations.
pdf Blood Typing (ABO Group & Rh Type) Collection Instructions.pdf
The ABO Group and Rh Type blood test is used to determine an individual’s blood group (A, B, AB, or O) and whether he or she is Rh positive or Rh negative. This document contains collection instructions. As of March 12, 2018, a separate lavender-top tube is required for Blood Type & RH test.
pdf Noroxymorphone Test Changes.pdf
The following changes were effective on April 11, 2018: Discontinued test - 70289 Noroxymorphone Confirmation, Quantitative, LC/MS, Urine.
pdf Prazepam Test Changes.pdf
The following changes were effective on April 19, 2018: Discontinued test - 70215 - Prazepam (Rx) Confirmation, Quantitative, LC/MS, Urine.
pdf Healthfirst Insurance’s In-Network Preferred Provider.pdf
In addition to the existing, extensive listing of HMO’s, PPO’s and conventional insurance plans we currently accept, we are pleased to announce that as of July 1, 2016, Lenco Diagnostic Laboratory Inc. has been selected as an In-Network Preferred Provider for Healthfirst Insurance Plan.
pdf Fecal Immunochemical Test (FIT).pdf
Fecal Immunochemical Test (FIT) is a screening test for hemoglobin in stool. It uses antibodies specific for human globin to detect the intact globin protein portion of hemoglobin, rather than the heme in hemoglobin A and hemoglobin S.
pdf Blood Typing (ABO Group & Rh Type).pdf
The ABO Group and Rh Type blood test is used to determine an individual’s blood group (A, B, AB, or O) and whether he or she is Rh positive or Rh negative.
pdf BD Vaginal Panel.pdf
BD MAX™ Vaginal Panel is the first FDA-authorized microbiome-based assay that detects the 3 most common infectious causes of vaginitis in addition to 2 drug-resistant yeast strains, all with the efficiency of 1 swab. It provides consistent, accurate results that surpass traditional 1st and 2nd generation methods for vaginitis detection.
pdf 2018 Annual Update.pdf
The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the recipients of the laboratory’s policies for test ordering and billing and provide certain other information regarding the laws and regulations that govern laboratory services. This Annual Laboratory Update is provided pursuant to that recommendation.
pdf Aetna’s In-Network Preferred Provider.pdf
In addition to the existing, extensive listing of HMO’s, PPO’s and conventional insurance plans we currently accept, we are pleased to announce that as of August 1, 2018, Lenco has been selected as a national, in-network, preferred lab provider for Aetna Inc.
pdf 2018 Annual Update 2 - Laboratory Compliance.pdf
As a participant in federally funded healthcare programs, Lenco delivers annual provider information and education regarding laboratory compliance, billing and coding guidelines, and information to our provider clients on the responsibilities we share. This update specifies current Medicare/Medicaid program requirements and Lenco’s policies.